Company: AEMD
Filing Date: 2025-09-05
Form Type: 424B4
Source: 0001683168-25-006701
Chunk: 2

Company: AETHLON MEDICAL INC
Filing Date: 2025-09-05
Form: 424B4
Chunk 2
---
holders (the “Inducement Offering”) identified in this
prospectus under the caption “Selling Securityholders” of up to 1,550,000 shares of our common stock
which are issuable upon the exercise of outstanding inducement warrants (the “Inducement Warrants”). We previously issued
Inducement Warrants to the Selling Securityholder in a private placement, pursuant to a Warrant Inducement Agreement dated March 16,
2025.

The Selling Securityholder may,
from time to time, sell, transfer or otherwise dispose of any or all of their common stock or interests in their common stock on any
stock exchange, market or trading facility on which the common stock is traded or in private transactions. These dispositions may be
at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices
determined at the time of sale, or at negotiated prices. See “Plan of Distribution” in this prospectus
for more information. We will not receive any proceeds from the resale or other disposition of the common stock by the Selling Securityholder.
However, we will receive the proceeds of any cash exercise of the Inducement Warrants. See “Use of Proceeds”
beginning on page 27 and “Plan of Distribution” beginning on page 40 of this prospectus for more information.
The offering will settle delivery versus payment (“DVP”)/receipt versus payment (“RVP”). Accordingly, we and
the placement agent have not made any arrangements to place investor funds in an escrow account or trust account since the placement
agent will not receive investor funds in connection with the sale of the securities offered hereunder.

Our common stock is traded
on the Nasdaq Capital Market (“Nasdaq”) under the symbol “AEMD.” On September 3, 2025, the last reported sale
price of our common stock as reported on Nasdaq was $1.35 per share. We are a “smaller reporting company” as defined under
the federal securities laws and, under applicable Securities and Exchange Commission rules, we have elected to comply with certain reduced
public company reporting and disclosure requirements.

You should read this prospectus,
together with additional information described under the headings “Where You Can Find More Information,”
carefully before you invest in any of our securities.

We have agreed to pay the placement
agent fees set forth in the table below, which assumes that we sell all of the